ECM
AXSM icon

Endurant Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Endurant Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11,254
Closed -$787K – 31
2023
Q3 		$787K Buy
+11,254
New +$841K 0.71% 33
2023
Q1 		– Sell
-11,264
Closed -$869K – 54
2022
Q4 		$869K Buy
+11,264
New +$673K 0.35% 40
2022
Q3 		– Sell
-15,246
Closed -$584K – 52
2022
Q2 		$584K Sell
15,246
-85,053
-85% -$2.69M 0.2% 45
2022
Q1 		$4.15M Buy
100,299
+44,670
+80% +$1.38M 1.09% 26
2021
Q4 		$2.1M Buy
55,629
+3,581
+7% +$132K 0.51% 40
2021
Q3 		$1.72M Buy
+52,048
New +$2.03M 0.39% 43
2020
Q2 		– Sell
-12,367
Closed -$728K – 61
2020
Q1 		$728K Buy
12,367
+1,216
+11% +$99.1K 0.33% 39
2019
Q4 		$1.15M Buy
+11,151
New +$450K 0.36% 42
2019
Q2 		– Sell
-52,268
Closed -$744K – 55
2019
Q1 		$744K Sell
52,268
-156,927
-75% -$1.46M 0.29% 53
2018
Q4 		$590K Buy
209,195
+114,010
+120% +$375K 0.31% 43
2018
Q3 		$328K Buy
+95,185
New +$282K 0.15% 71

Other funds holding AXSM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Endurant Capital Management's AXSM Position: Q4 2023 in Review

Endurant Capital Management sold out of Axsome Therapeutics (AXSM) in Q4 2023, closing a stake of 11,254 shares — an estimated $787K sold.

Endurant Capital Management first reported a position in AXSM in Q3 2018 and held it in 11 quarters. The position peaked at $4.15M in Q1 2022. 244 funds tracked by Wall St. Rank hold AXSM as of Q4 2023.

  • Endurant Capital Management reported no remaining Axsome Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Endurant Capital Management sold 11,254 Axsome Therapeutics shares in Q4 2023, an estimated $787K.
  • Endurant Capital Management first reported a position in Axsome Therapeutics in Q3 2018 and held it in 11 quarters.
  • Endurant Capital Management's Axsome Therapeutics position peaked at $4.15M in Q1 2022.
  • 244 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2023.

Based on Endurant Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.